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Abstract
A recent study published by Sjoblom and colleagues [1] performed comprehensive sequencing of
13,023 human genes and identified mutations in genes specific to breast and colorectal tumors,
providing insight into organ-specific tumor biology. Here we present a systematic analysis of the
functional classifications of Sjoblom’s “CAN” genes, a subset of these validated mutant genes that
identify novel organ-specific biological themes and molecular pathways associated with disease-
specific etiology. This analysis links four somatically mutated genes associated with diverse
oncological types to colorectal and breast cancers through established TGF-β1 regulated interactions,
revealing mechanistic differences in these cancers and providing potential diagnostic and therapeutic
targets.
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Introduction
Tumors arise from genetic alterations occurring within a single cell. These are passed to
daughter cells that accumulate additional mutations within oncogenes, tumor-suppressor
genes, and genomic stability genes [2], which ultimately give rise to tumorigenesis. Although
many gene-specific mutations have been discovered in a wide range of cancers, the reference
human genome sequence and improved high-throughput sequencing technologies provide the
opportunity for an unbiased approach to identification of potentially important mutations. Such
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an approach was used in a recent study by Sjoblom and colleagues [1] that examined 14,661
transcripts from 13,023 genes (120,839 exons) from the consensus coding sequences (CCDS)
database [3] in 11 breast tumors, 11 colorectal tumors, and two normal control samples. A
collection of 1,149 potential mutations was detected from which a subset of 236 somatically
mutated genes was experimentally validated. Statistical analysis of these validated genes then
identified a group of candidate cancer genes (CAN genes) that had a higher baseline frequency
of mutation than expected by chance: 122 in breast and 69 in colorectal cancers. Grouping
organ-specific CAN mutant coding sequences into biological themes based on Gene Ontology
terms, Sjoblom et al. associated these genes with specific cellular processes, including cellular
adhesion and motility, signal transduction, transcriptional regulation, transport, cellular
metabolism, intracellular trafficking, and RNA metabolism among others. Moreover, they
identified significant differences in the mutation spectra of human breast and colorectal
cancers, suggesting distinct mutagenic and etiologic pathways.
While enlightening, this qualitative approach to gene functional analysis does not take into
account the relative representation of different functional classes associated with the entire
collection of genes surveyed. For example, since signal transduction genes are highly
represented in the CCDS database, the likelihood of a mutation occurring by chance within
these genes is greater than in other, less well-represented classes. With this in mind, we
reanalyzed the CAN gene dataset from Sjoblom et al. to identify biological functional classes
and pathways in which greater numbers of genes accumulate mutations than one would expect
by chance. Application of a statistically-based categorical representation approach allows one
to move beyond looking at individual genes to identify systems, rather than individual genes,
that may be associated with disease development and progression. The use of such methods,
supplemented by text mining applied to PubMed abstracts associated with those genes, allowed
us to identify novel associations of numerous oncological types to colorectal and breast cancers
through established TGF-β1 regulated interactions.
Results and Discussion
We analyzed the 69 CAN genes found by Sjoblom and associates [1] to be mutated in colorectal
cancer, using EASE [4]. EASE uses Fisher’s Exact Test to identify over-represented functional
classes relative to the distribution of class assignments for genes in a reference dataset, in this
case the CCDS database from which the genes to be sequenced were selected. Functional class
assignments included Gene Ontology [5] assignments, chromosome location, phenotype, Pfam
domains [6], Swiss-Prot keywords [7], BBID assignments [8], and the GenMAPP [9] and
KEGG pathway databases [10]. For CAN genes falling within those over-represented classes,
we then used Chilibot [11] to perform text mining to delineate associations between the mutant
genes and various cancers.
We found 37 CAN genes associated with significantly over-represented biological classes.
Twenty of these, including APC, TP53 and TGFBR2, have been previously associated with
colorectal cancer; these largely represent TGF-β signaling, disease mutation, alternative
splicing, and proteins containing MH1 and MH2 domains (Table 1). Although none of the
MH1-containing proteins were found to have mutations in the active domain, of the MH2-
containing proteins, 70% of the CAN mutations identified by Sjoblom et al were found within
the MH2 domain itself. This percentage was not statistically significant according to Chi-
square analysis, however, due to the small sample size. The remaining 17, including CAN genes
associated with Metalloendopeptidase activity and alternative splicing and those containing a
Fibronectin type III domain, have not been clinically linked to colorectal cancer as determined
by text-mining [11].
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The most prominent association revealed in this analysis was the role of TGF-β1 regulation,
with 17 of the 37 CAN genes having an established relationship to this process (Figure 1A).
While mutational inactivation of TGFBR2 is common in approximately 20–30% of all
colorectal cancers [12] and 70% of colorectal cancers with high degree microsatellite instability
[13], we find a significant number of additional TGF-β1 regulated genes are also mutated in
colorectal cancer, suggesting a much more significant role for this pathway.
Of the 17 TGF-β1 regulated CAN genes, PTPRU and RUNX1T1 have not been clinically linked
to colorectal cancer. PTPRU is implicated in a number of cellular processes including cell
growth, cell-cell recognition, cell adhesion, differentiation, mitotic cycle, and oncogenic
transformation. The expression of this gene is regulated, in-part, by RAS and upregulated in
Jurkat T lymphoma cells [14]. In addition, over expression of PTPRU in SW480 cells
significantly suppresses cell proliferation and migration, suggesting colorectal carcinomas
with mutant PTPRU may be more aggressive [15]. Although RUNX1T1 (ETO) has not been
implicated in TGF-β1 regulation in colorectal cancer, TGF-β1 is a potent endogenous negative
regulator of hematopoiesis and the t(8;21)(q22;q22) translocation of this gene, which produces
a chimeric protein (AML1-ETO), is one of the most common cytogenetic abnormalities in
acute myeloid leukemia [16]. These data implicate aberrant TGF-β1 regulation as a major
contributor to disease etiology of colorectal cancer.
This high rate of hits in a single pathway is interesting, particularly since other pathways known
to be involved in colorectal cancer were not targeted for mutations in the same manner. For
example only six of the sixty-two genes in the WNT/beta-catenin pathway (SMAD2, SMAD3,
SMAD4, TP53, TCF7L2, APC) were identified, despite the fact that this pathway is abnormally
regulated in 80% of colorectal cancers [17].
Of the 122 CAN genes Sjoblom and colleagues [1] identified in breast cancer, we found 24
associated with over-represented biological classes. Only five CAN genes involved in cell
adhesion molecule activity and GTPase activation have a previously described relationship to
breast cancer [11] (Table 1). The remaining 19 CAN genes include those linked to JNK
activation and proteins containing Spectrin repeat domains. Moreover, all enriched breast
cancer terms can be linked to disease-specific cytoskeleton regulation, representing a variety
of cellular functions including cell adhesion, migration, proliferation, apoptosis, and
differentiation. This suggests cytoskeletal disregulation may be a major contributor to general
breast cancer etiology. However, it is well known that breast cancer is a molecularly diverse
disease in which subgroups are distinguished by hormone receptor status and gene expression
profiles [18]. It is, therefore, unfortunate that more complete data on these tumors are
unavailable as it might provide additional insight.
Nevertheless, the available data allows one to draw some interesting comparisons. Unlike
colorectal cancer, somatic mutation in breast cancer appears largely TGF-β1 independent. Only
3 of the 24 CAN genes identified in our analysis have a known association to TGF-β1 regulation
(Figure 1B) and two of these (COL7A1 and SPTAN1) have no clinical link to breast cancer.
Type VII collagen (COL7A1) defects cause recessive dystrophic epidermolysis bullosa
(RDEB), a blistering skin disorder often accompanied by epidermal cancers. Tumor-stroma
interactions mediated by collagen VII promote neoplasia in RDEB patients and may contribute
to their increased susceptibility to squamous cell carcinoma. COL7A1 is activated by TGF-β1
via SMAD transcription factors and JUN [19]. Alpha II-Spectrin (SPTAN1) is upregulated and
associated with tumorigenesis in ovarian cancer. Moreover, TGF-β1 promotes caspase 3-
independent cleavage of SPTAN1, suggesting mutation of a distinct apoptotic pathway in breast
cancer [20].
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Our systematic functional classification, comprised of statistical tests for over-represented
biological themes and text-mining, provides support for the manually derived themes of recent
work by Sjoblom et al. [1] and allowed us to identify additional mechanistic insights into the
differences between breast and colorectal cancers. In particular, we have identified disease-
specific functional classes and somatically mutated molecular pathways that have not been
previously reported. We have also found evidence supporting a potentially more significant
role for TGF-β1 regulation in colorectal tumorigenesis; a role which highlights mechanistic
differences between human breast and colorectal cancers. Furthermore, our analysis identifies
four frequently mutated genes (PTPRU, RUNX1T, COL7A, SPTAN1) associated with TGF-β
regulation that may represent diagnostic and therapeutic targets.
Given the rapid advances in next-generation sequencing technology, we expect to see
increasing numbers of sequence-based studies that will expand the catalogue of potentially
causative mutations in a wide range of disease states. As we have learned from gene expression
studies, functional analysis of the resulting gene lists using now well-established classification
systems such as GO can help put the work into an intellectual framework that provides the
opportunity for hypothesis generation and mechanistic interpretation. However, such analysis
must be applied rigorously to avoid reaching conclusions that reflect trends in the data rather
than patterns in the gene set that was sampled.
Materials and Methods
Somatically mutated breast and colorectal candidate cancer genes (CAN genes) identified by
Sjoblom et al. [1] were subjected to a functional category representational analysis using EASE
[4] as implemented in MeV [21]. EASE uses Fisher’s Exact Test to identify functional classes
that appear with a greater likelihood than by chance and calculates associated p-values based
on the hypergeometric distribution. Here we analyzed representation for Gene Ontology [5]
assignments, chromosome location, phenotype, Pfam domains [6], Swiss-Prot keywords [7],
BBID assignments [8], and the GenMAPP [9] and KEGG pathways [10]. In the analysis of
GO terms, EASE uses the structure of the GO hierarchy and performs an analysis at each level.
One potential limitation of this method is that it identifies as significant those pathways and
functional classes that have many genes which have accumulated mutations and does not
account for the mutation rates of individual genes.
Chilibot [11] was then used to identify associations between somatically mutated CAN genes
belonging to the enriched functional classes and disease state. Chilibot is a web-based
application that uses natural language processing to search PubMed abstracts for relationships
between genes of interest. Each gene is compared with each other gene in the query group and
assigned a relationship (stimulatory, inhibitory, neutral, parallel and abstract co-occurrence)
based data in the abstract.
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Figure 1.
Chilibot text mining analysis of somatically mutated CAN genes in colorectal and breast
cancers and their relationship to TGF-β regulation. A. Somatically mutated CAN genes in
colorectal cancer. B. Somatically mutated CAN genes in breast cancer.  Queried terms. 
Interactive relationship (stimulative).  Interactive relationship (inhibitory).  Interactive
relationship (both stimulative and inhibitory).  Interactive relationship (neutral).  Non-
interactive (i.e. parallel) relationship  Abstract co-occurrence only. Numbers within icons
represent PubMed abstracts supporting each association. * Genes have not been clinically
implicated in respective cancer states.
Chittenden et al. Page 6
Genomics. Author manuscript; available in PMC 2009 June 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Chittenden et al. Page 7
Ta
bl
e 
1
E
A
SE
 A
na
ly
si
s
O
ve
r-
re
pr
es
en
te
d 
fu
nc
tio
na
l c
la
ss
es
 o
f m
ut
at
ed
 C
AN
 g
en
es
 fo
un
d 
in
 b
re
as
t a
nd
 co
lo
re
ct
al
 ca
nc
er
. T
he
 li
st
 o
f f
un
ct
io
na
l a
nn
ot
at
io
n 
cl
as
se
s
an
al
yz
ed
 in
cl
ud
e:
 G
O
 te
rm
s f
or
 b
io
lo
gi
ca
l p
ro
ce
ss
, m
ol
ec
ul
ar
 fu
nc
tio
n,
 an
d 
ce
llu
la
r c
om
po
ne
nt
; c
hr
om
os
om
e l
oc
at
io
n;
 p
he
no
ty
pe
; p
ro
te
in
fa
m
ily
 (
Pf
am
) 
do
m
ai
n;
 S
w
is
s-
Pr
ot
 k
ey
w
or
ds
; B
io
lo
gi
ca
l B
io
ch
em
ic
al
 I
m
ag
e 
D
at
ab
as
e 
(B
B
ID
); 
G
en
e 
M
ap
 A
nn
ot
at
or
 a
nd
 P
at
hw
ay
Pr
of
ile
r (
G
en
M
A
PP
) a
nd
 K
yo
to
 E
nc
yc
lo
pe
di
a 
of
 G
en
es
 a
nd
 G
en
om
es
 (K
EG
G
) p
at
hw
ay
s. 
H
er
e 
Po
p 
Si
ze
 is
 th
e 
nu
m
be
r o
f C
C
D
S 
ge
ne
s
as
si
gn
ed
 to
 a
 p
ar
tic
ul
ar
 a
nn
ot
at
io
n 
cl
as
s. 
Po
p 
H
its
 is
 th
e 
nu
m
be
r o
f C
C
D
S 
se
qu
en
ce
s a
ss
ig
ne
d 
to
 a
 p
ar
tic
ul
ar
 a
nn
ot
at
io
n 
te
rm
. L
is
t S
iz
e
in
di
ca
te
s 
th
e 
nu
m
be
r o
f m
ut
at
ed
 g
en
es
 w
ith
 a
ss
ig
nm
en
ts
 in
 e
ac
h 
an
no
ta
tio
n 
cl
as
s 
an
d 
th
e 
Li
st
 H
its
 is
 th
e 
nu
m
be
r a
ss
oc
ia
te
d 
w
ith
 e
ac
h
pa
rti
cu
la
r t
er
m
. T
he
 F
is
he
r’
s E
xa
ct
 c
ol
um
n 
lis
ts
 th
e 
p-
va
lu
e 
fr
om
 F
is
he
r’
s E
xa
ct
 te
st
 a
nd
 P
ro
b 
A
na
l c
ol
um
n 
lis
ts
 p
-v
al
ue
s c
or
re
ct
ed
 fo
r
m
ul
tip
le
 te
st
in
g 
vi
a 
re
sa
m
pl
in
g.
 G
en
es
 h
ig
hl
ig
ht
ed
 in
 y
el
lo
w
 h
av
e 
no
t b
ee
n 
cl
in
ic
al
ly
 im
pl
ic
at
ed
 in
 re
sp
ec
tiv
e 
ca
nc
er
 ty
pe
s.
C
ol
or
ec
ta
l C
an
ce
r
C
at
eg
or
y
A
cc
es
si
on
T
er
m
L
is
t H
its
L
is
t S
iz
e
Po
p 
H
its
Po
p 
Si
ze
Fi
sh
er
's
 E
xa
ct
Pr
ob
 A
na
l
CA
N
 G
en
es
G
O
 B
io
lo
gi
ca
l P
ro
ce
ss
G
O
:0
00
71
67
En
zy
m
e 
lin
ke
d 
re
ce
pt
or
 p
ro
te
in
 si
gn
al
in
g
pa
th
w
ay
8
61
14
4
10
01
9
2.
3×
10
−6
1.
0×
10
−3
EP
H
B
6,
 P
TP
R
U
, T
G
FB
R
2,
EP
H
A
3,
 P
TP
R
D
, S
M
A
D
4,
SM
A
D
3,
 S
M
A
D
2
PF
A
M
 d
om
ai
n
PF
03
16
6
M
H
2 
do
m
ai
n
3
46
6
56
73
9.
8×
10
−6
4.
0×
10
−3
SM
A
D
4,
 S
M
A
D
3,
 S
M
A
D
2
PF
A
M
 d
om
ai
n
PF
03
16
5
M
H
1 
do
m
ai
n
3
46
6
56
73
9.
8×
10
−6
4.
0×
10
−3
SM
A
D
4,
 S
M
A
D
3,
 S
M
A
D
2
G
O
 M
ol
ec
ul
ar
 F
un
ct
io
n
G
O
:0
00
42
22
M
et
al
lo
en
do
pe
pt
id
as
e 
ac
tiv
ity
6
63
86
10
19
7
1.
4×
10
−5
2.
0×
10
−3
A
D
A
M
29
, A
D
A
M
TS
L3
,
A
D
A
M
TS
18
, A
D
A
M
TS
15
,
U
Q
C
R
C
2,
 M
M
P2
PF
A
M
 d
om
ai
n
PF
00
04
1
Fi
br
on
ec
tin
 ty
pe
 II
I d
om
ai
n
6
46
77
56
73
3.
1×
10
−5
1.
0×
10
−2
C
H
L1
, E
PH
B
6,
 P
TP
R
U
,
C
N
TN
4,
 E
PH
A
3,
 P
TP
R
D
G
O
 B
io
lo
gi
ca
l P
ro
ce
ss
G
O
:0
00
71
79
TG
Fb
et
a 
re
ce
pt
or
 si
gn
al
in
g 
pa
th
w
ay
4
61
32
10
01
9
3.
9×
10
−5
1.
7×
10
−2
TG
FB
R
2,
 S
M
A
D
4,
 S
M
A
D
3,
SM
A
D
2
G
O
 B
io
lo
gi
ca
l P
ro
ce
ss
G
O
:0
00
71
78
Tr
an
s-
m
em
br
an
e r
ec
ep
to
r p
ro
te
in
 se
rin
e /
th
re
on
in
e 
ki
na
se
 si
gn
al
in
g 
pa
th
w
ay
4
61
36
10
01
9
6.
3×
10
−5
2.
4×
10
−2
TG
FB
R
2,
 S
M
A
D
4,
 S
M
A
D
3,
SM
A
D
2
Sw
is
sP
ro
t k
ey
w
or
d
D
is
ea
se
 m
ut
at
io
n
14
44
67
5
65
65
7.
9×
10
−5
5.
0×
10
−3
TP
53
, T
B
X
22
, A
PC
, P
K
H
D
1,
A
B
C
A
1,
 T
G
FB
R
2,
 E
R
C
C
6,
G
A
LN
S,
 R
ET
, G
N
A
S,
 N
F1
,
SM
A
D
4,
 K
R
A
S,
 S
M
A
D
2
Ph
en
ot
yp
e
C
ol
or
ec
ta
l c
an
ce
r
4
17
22
12
02
1.
7×
10
−4
1.
5×
10
−2
TP
53
, A
PC
, T
G
FB
R
2,
 K
R
A
S
G
O
 B
io
lo
gi
ca
l P
ro
ce
ss
G
O
:0
00
71
83
SM
A
D
 p
ro
te
in
 h
et
er
om
er
iz
at
io
n
2
61
4
10
01
9
2.
2×
10
−4
5.
2×
10
−2
SM
A
D
4,
 S
M
A
D
2
G
O
 B
io
lo
gi
ca
l P
ro
ce
ss
G
O
:0
00
71
82
C
om
m
on
-p
ar
tn
er
 S
M
A
D
 p
ro
te
in
ph
os
ph
or
yl
at
io
n
2
61
4
10
01
9
2.
2×
10
−4
5.
2×
10
−2
SM
A
D
4,
 S
M
A
D
2
Sw
is
sP
ro
t k
ey
w
or
d
A
lte
rn
at
iv
e 
sp
lic
in
g
19
44
13
10
65
65
3.
7×
10
−4
3.
8×
10
−2
TP
53
, A
C
SL
5,
 K
C
N
Q
5,
C
D
46
, A
PC
, A
D
A
M
29
,
PK
H
D
1,
 R
U
N
X
1T
1,
 E
V
L,
G
U
C
Y
1A
2,
 E
PH
A
3,
 M
A
P2
,
EY
A
4,
 P
TP
R
D
, G
N
A
S,
 N
F1
,
K
R
A
S,
 S
M
A
D
2,
 S
FR
S6
Ph
en
ot
yp
e
Pa
nc
re
at
ic
 c
an
ce
r
2
17
4
12
02
1.
1×
10
−3
3.
8×
10
−2
TP
53
, S
M
A
D
4
B
B
ID
 p
at
hw
ay
84
.U
bi
qu
iti
na
tio
n_
Pa
th
w
ay
s_
C
el
l_
C
yc
le
2
3
12
29
1
4.
6×
10
−3
4.
1×
10
−2
A
PC
, C
D
24
8
G
en
M
A
PP
 p
at
hw
ay
H
um
an
/G
en
 M
A
PP
.o
rg
H
s_
TG
F 
B
et
a 
Si
gn
al
in
g 
Pa
th
w
ay
4
15
41
11
54
1.
4×
10
−3
2.
0×
10
−2
TG
FB
R
2,
 S
M
A
D
4,
 S
M
A
D
3,
SM
A
D
2
B
re
as
t C
an
ce
r
C
at
eg
or
y
A
cc
es
si
on
Te
rm
Li
st
 H
its
Li
st
 S
iz
e
Po
p 
H
its
Po
p 
Si
ze
Fi
sh
er
's 
Ex
ac
t
Pr
ob
 A
na
l
C
AN
 G
en
es
G
O
 M
ol
ec
ul
ar
 F
un
ct
io
n
G
O
:0
00
51
94
ce
ll 
ad
he
si
on
 m
ol
ec
ul
e 
ac
tiv
ity
13
10
9
26
4
10
19
7
4.
4×
10
−6
2.
0×
10
−3
A
D
A
M
12
, C
D
H
10
, C
D
H
20
,
C
O
L1
1A
1,
 C
O
L7
A
1,
IC
A
M
5,
 IT
G
A
9,
 N
R
C
A
M
,
R
A
PH
1,
 T
EC
TA
, T
H
B
S3
,
PC
D
H
B
15
, C
O
L1
9A
1
G
O
 B
io
lo
gi
ca
l P
ro
ce
ss
G
O
:0
00
72
57
ac
tiv
at
io
n 
of
 JN
K
 a
ct
iv
ity
3
10
4
5
10
01
9
1.
1×
10
−5
1.
0×
10
−3
D
B
N
1,
 R
A
SG
R
F2
, M
A
P3
K
6
Genomics. Author manuscript; available in PMC 2009 June 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Chittenden et al. Page 8
C
ol
or
ec
ta
l C
an
ce
r
C
at
eg
or
y
A
cc
es
si
on
T
er
m
L
is
t H
its
L
is
t S
iz
e
Po
p 
H
its
Po
p 
Si
ze
Fi
sh
er
's
 E
xa
ct
Pr
ob
 A
na
l
CA
N
 G
en
es
Sw
is
sP
ro
t k
ey
w
or
d
G
TP
as
e 
ac
tiv
at
io
n
5
71
36
65
65
3.
7×
10
−5
3.
0×
10
−3
C
EN
TB
1,
 R
A
P1
G
A
P,
C
EN
TG
1,
 R
A
SA
L2
,
ST
A
R
D
8
PF
A
M
 d
om
ai
n
PF
00
43
5
Sp
ec
tri
n 
re
pe
at
3
62
11
56
73
1.
9×
10
−4
3.
8×
10
−2
SP
TA
N
1,
 M
A
C
F1
, S
Y
N
E2
Genomics. Author manuscript; available in PMC 2009 June 1.
